EP3341011A4 - Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen - Google Patents

Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen Download PDF

Info

Publication number
EP3341011A4
EP3341011A4 EP16825301.1A EP16825301A EP3341011A4 EP 3341011 A4 EP3341011 A4 EP 3341011A4 EP 16825301 A EP16825301 A EP 16825301A EP 3341011 A4 EP3341011 A4 EP 3341011A4
Authority
EP
European Patent Office
Prior art keywords
interleukin
receptor
inflammatory diseases
peptide inhibitors
treat inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16825301.1A
Other languages
English (en)
French (fr)
Other versions
EP3341011A2 (de
Inventor
Ashok Bhandari
Gregory BOURNE
Xiaoli Cheng
Brian Troy FREDERICK
Jie Zhang
Dinesh V. Patel
David Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of EP3341011A2 publication Critical patent/EP3341011A2/de
Publication of EP3341011A4 publication Critical patent/EP3341011A4/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP16825301.1A 2015-07-15 2016-07-15 Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen Pending EP3341011A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (2)

Publication Number Publication Date
EP3341011A2 EP3341011A2 (de) 2018-07-04
EP3341011A4 true EP3341011A4 (de) 2019-02-20

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16825301.1A Pending EP3341011A4 (de) 2015-07-15 2016-07-15 Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen

Country Status (23)

Country Link
EP (1) EP3341011A4 (de)
JP (1) JP6858174B2 (de)
KR (1) KR102513978B1 (de)
CN (1) CN108348580B (de)
AU (1) AU2016293619B2 (de)
BR (1) BR112018000691A2 (de)
CA (1) CA2991984A1 (de)
CL (3) CL2018000128A1 (de)
CO (1) CO2018000349A2 (de)
CR (1) CR20180029A (de)
DO (1) DOP2018000010A (de)
EA (1) EA035733B9 (de)
EC (1) ECSP18002929A (de)
HK (2) HK1257747A1 (de)
IL (1) IL256827A (de)
MX (1) MX2018000542A (de)
NI (1) NI201800008A (de)
PE (1) PE20180571A1 (de)
PH (1) PH12018500086A1 (de)
SG (1) SG10201912066SA (de)
SV (1) SV2018005614A (de)
UA (1) UA123772C2 (de)
WO (1) WO2017011820A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014145561A2 (en) 2013-03-15 2014-09-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
CN109776525B (zh) 2013-04-19 2022-01-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
ES2890600T3 (es) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
KR102482790B1 (ko) 2014-07-17 2022-12-29 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109195618A (zh) 2016-03-23 2019-01-11 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
EP3570864A4 (de) * 2017-01-18 2020-12-30 Protagonist Therapeutics, Inc. Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP3681900A4 (de) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Opioidagonistpeptide und verwendungen davon
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化(上海)新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114341161A (zh) * 2019-07-10 2022-04-12 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3819307A1 (de) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutische derivate von interleukin-22
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JOP20220169A1 (ar) * 2020-01-15 2023-01-30 Janssen Biotech Inc مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
KR20240034223A (ko) * 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists
US20240218014A1 (en) * 2022-11-21 2024-07-04 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
WO2024155547A2 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
WO2024163643A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183755A1 (en) * 2010-03-31 2013-07-18 Grant Gallagher Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2692037A1 (en) * 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2015054500A2 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183755A1 (en) * 2010-03-31 2013-07-18 Grant Gallagher Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017011820A2 *

Also Published As

Publication number Publication date
AU2016293619A1 (en) 2018-02-01
DOP2018000010A (es) 2018-03-30
CO2018000349A2 (es) 2018-07-10
NI201800008A (es) 2018-06-29
ECSP18002929A (es) 2018-03-31
SV2018005614A (es) 2018-05-22
AU2016293619B2 (en) 2021-02-25
CL2018003322A1 (es) 2019-01-18
BR112018000691A2 (pt) 2018-09-18
EA201890325A1 (ru) 2018-06-29
SG10201912066SA (en) 2020-02-27
JP2018522008A (ja) 2018-08-09
CR20180029A (es) 2018-06-05
JP6858174B2 (ja) 2021-04-14
HK1259149A1 (zh) 2019-11-29
CN108348580A (zh) 2018-07-31
EA035733B9 (ru) 2021-01-14
CL2021000343A1 (es) 2021-08-06
CN108348580B (zh) 2022-05-10
HK1257747A1 (zh) 2019-10-25
UA123772C2 (uk) 2021-06-02
KR20180030663A (ko) 2018-03-23
WO2017011820A3 (en) 2017-02-23
CL2018000128A1 (es) 2018-06-15
EP3341011A2 (de) 2018-07-04
PH12018500086A1 (en) 2018-07-30
KR102513978B1 (ko) 2023-03-27
MX2018000542A (es) 2018-06-27
EA035733B1 (ru) 2020-07-31
PE20180571A1 (es) 2018-04-04
CA2991984A1 (en) 2017-01-19
IL256827A (en) 2018-03-29
WO2017011820A2 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
HK1259149A1 (zh) 白細胞介素-23受體的肽抑制劑以及其治療炎症性疾病的用途
IL285614A (en) Oral peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory bowel diseases
EP3570864A4 (de) Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen
EP3820883A4 (de) Peptidinhibitoren des interleukin-23-rezeptors und deren verwendung zur behandlung entzündlicher erkrankungen
IL253796A0 (en) Therapeutically active compounds and methods of use
IL251246A0 (en) Therapeutically active compounds and methods of use
EP3151833A4 (de) Mth1-inhibitoren zur behandlung von entzündungs- und autoimmunerkrankungen
IL250318B (en) Protein kinase c inhibitors and methods of using them
EP3047024A4 (de) Zusammensetzungen und verfahren zur behandlung von autoimmun- und entzündungserkrankungen und -leiden
EP3116898A4 (de) Verwendung von aav-exprimiertem m013-protein als entzündungshemmendes therapeutikum
IL289628A (en) Peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory diseases
IL253118A0 (en) Methods for treating inflammatory diseases
HK1211471A1 (en) Treating th2-mediated diseases by inhibition of bromodomain- comprising proteins brd7 and brd9 brd7 brd9 th2
HK1252037A1 (zh) 治療炎性疾病的方法
EP3157531A4 (de) Verfahren und zusammensetzungen zur stimulierung des intestinalen enteroendokrinen systems zur behandlung von erkrankungen oder zuständen in zusammenhang damit
EP3503903A4 (de) Ascarosidbehandlung von autoimmun- und entzündungserkrankungen
EP3148575A4 (de) Verfahren und zusammensetzungen zur behandlung von allergie- und entzündungskrankheiten
EP3408413A4 (de) Vorhersage der therapeutischen reaktion bei entzündungserkrankungen
EP3288379A4 (de) Peptidzusammensetzungen und verfahren zur verwendung
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
EP3393460A4 (de) Zusammensetzungen und verfahren zur behandlung von mvid und verwandten erkrankungen
EP3313427A4 (de) Therapeutische peptide und verfahren zur verwendung davon
EP3139944A4 (de) Verwendung eines peptids zur behandlung angiogenesebedingter erkrankungen
IL241934A (en) Inhibitory peptides for the treatment of inflammatory diseases
EP3534932A4 (de) Behandlung von krankheiten im zusammenhang mit igfb3 und dessen rezeptor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190121

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/08 20060101ALI20190115BHEP

Ipc: A61K 38/20 20060101AFI20190115BHEP

Ipc: C07K 14/54 20060101ALI20190115BHEP

Ipc: C07K 7/06 20060101ALI20190115BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257747

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTAGONIST THERAPEUTICS, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038200000

Ipc: C07K0007060000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALN20240724BHEP

Ipc: A61P 37/06 20060101ALI20240724BHEP

Ipc: A61P 37/02 20060101ALI20240724BHEP

Ipc: A61P 35/00 20060101ALI20240724BHEP

Ipc: A61P 29/00 20060101ALI20240724BHEP

Ipc: A61P 19/02 20060101ALI20240724BHEP

Ipc: A61P 17/06 20060101ALI20240724BHEP

Ipc: A61P 15/00 20060101ALI20240724BHEP

Ipc: A61P 11/06 20060101ALI20240724BHEP

Ipc: A61P 11/02 20060101ALI20240724BHEP

Ipc: A61P 7/00 20060101ALI20240724BHEP

Ipc: A61P 3/10 20060101ALI20240724BHEP

Ipc: A61P 3/00 20060101ALI20240724BHEP

Ipc: A61P 1/18 20060101ALI20240724BHEP

Ipc: A61P 1/16 20060101ALI20240724BHEP

Ipc: A61P 1/04 20060101ALI20240724BHEP

Ipc: C07K 7/08 20060101ALI20240724BHEP

Ipc: C07K 7/06 20060101AFI20240724BHEP

INTG Intention to grant announced

Effective date: 20240806